The prescription drug Eltrombopag 50 mg, which contains the active component Eltrombopag INN, is mainly used to treat various hematological disorders and forms of thrombocytopenia, or low platelet counts. Eltrombopag, which is produced under stringent quality control guidelines, is designed to enable patients who require ongoing support for blood clotting function produce more platelets. Patients with severe aplastic anemia, hepatitis C-related thrombocytopenia, and persistent immune thrombocytopenic purpura (ITP) benefit most from it.

Active Ingredient: Eltrombopag INN

Eltrombopag is categorized as an agonist of the thrombopoietin receptor. It functions by encouraging the production of more platelets in the bone marrow, which are necessary for blood coagulation. This pharmaceutical activity enhances the general quality of life and lowers the risk of bleeding in individuals with low platelet counts.

Indications and Uses

Eltrombopag 50 mg is used to treat a number of ailments:

Immune thrombocytopenic purpura chronica (ITP):

For patients of all ages who have not responded adequately to immunoglobulins, corticosteroids, or splenectomy.

It lowers the requirement for rescue therapy and raises platelet levels.

Chronic Hepatitis C with Thrombocytopenia:

used to enable the start and continuation of interferon-based therapy in patients with chronic hepatitis C.

aids in controlling low platelet counts, which are frequently a consequence of antiviral therapy.

SAA, or severe aplastic anemia:

for those suffering from severe aplastic anemia who have not responded well to immunosuppressive treatment.

occasionally used with additional immunosuppressive medications.

Dosage and Administration

Usually taken orally once a day, Eltrombopag 50 mg can be taken with or without food. To guarantee constant absorption, patients are recommended to take it either consistently with food or consistently without food.

For adults with ITP and hepatitis C-associated thrombocytopenia, 50 mg once daily is the typical initial dosage.

Pediatric patients and dose modifications: Age, weight, and certain medical problems can all affect the dosage. To track platelet counts and modify dosage appropriately, routine blood tests are necessary.

A lower initial dose can be necessary for patients with hepatic impairment or those of East Asian heritage.

Mechanism of Action

Eltrombopag INN) attaches itself to hematopoietic stem cells and megakaryocyte precursors and activates their thrombopoietin receptor (also known as TPO-R or c-Mpl). This increases the generation of platelets in the bone marrow by promoting the growth and differentiation of these cells into mature megakaryocytes. Eltrombopag avoids possible cross-reactivity by binding to a different location on the receptor than endogenous thrombopoietin.

Side Effects and Precautions

Typical adverse effects:

Feeling queasy

Weariness

A headache

Having diarrhea

Elevated liver enzymes

Serious but Infrequent Adverse Effects:

Liver damage, or hepatotoxicity

Events involving thromboembolism (blood clots)

Development of cataracts

Formation of bone marrow reticulin

Precautions:

Tests for liver function should be performed both prior to and during treatment.

To prevent the risk of thrombosis from too high platelet levels, platelet counts need to be routinely checked.

Use during pregnancy is not advised unless absolutely necessary.

Before using, nursing mothers should speak with their healthcare provider.

Storage and Handling

Keep out of direct sunlight and dampness and store below 30°C in a dry location.

Keep out of children’s reach.

After the expiration date indicated on the container, do not use.

Packaging and Availability

For convenience, Eltrombopag 50 mg tablets are usually packaged in blister strips. For patient safety and accurate identification, the container is tamper-proof and prominently labeled.

Why Choose Eltrombopag 50 mg?

Clinically Proven: Eltrombopag has consistently shown efficacy and safety, supported by clinical research and worldwide use.

Assurance of Quality: Produced in accordance with strict pharmaceutical guidelines to guarantee superior potency and purity.

Better Patient Outcomes: Lessens the requirement for emergency platelet transfusions and bleeding episodes.

Conclusion

Eltrombopag 50 mg is a vital therapeutic option for managing chronic ITP, hepatitis C-associated thrombocytopenia, and severe aplastic anemia. By effectively increasing platelet counts, it offers a reliable and convenient solution for patients at risk of bleeding complications. Always consult a healthcare professional before starting or adjusting the dosage of Eltrombopag.

Order Now At Mdx Pharma bd….

To order from MDX Pharma BD, visit their website at https://mdxpharmabd.com, where you can browse products and place orders online. For inquiries or orders via email, contact emedicarepharma@gmail.com. Alternatively, call (+88) 01929123476. Their address is 29, Abdullahpur, Uttara, Dhaka-1230, Bangladesh.

1. What is the purpose of Eltrombopag 50 mg?
Low platelet counts brought on by chronic hepatitis C virus (HCV) infection or chronic immunological (idiopathic) thrombocytopenic purpura (ITP) are treated with Elopag 50mg Tablet. Additionally, severe aplastic anemia is treated with it. Eltrombopag 50mg Tablet is an agonist of thrombopoietin.

2. For what number of days is eltrombopag recommended?
For adults and children aged 12 and up, start with 150 mg once day for six months. A smaller dose may be used for some patients at first. If necessary, your doctor may change your dosage. For children aged 6 to 11, take 75 mg once daily for six months.

3. Eltrombopag: is it safe?
Our results supported the safety and effectiveness of eltrombopag in treating immunological thrombocytopenia and were consistent with other published research. However, to improve our findings, additional clinical trials are required.

4. What is the eltrombopag success rate?
By day 15, over 80% of patients receiving the two highest doses of eltrombopag had seen an increase in their platelet count; this increase allowed the platelets to get closer to their normal range. Patients receiving a daily dose of 50 or 75 mg, respectively, showed median platelet counts of 88% and 81%.